Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer (PLEASURABLE)
Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer: a Multi-center Phase Ib/II Study
Sponsor: Fudan University
This PHASE1/PHASE2 trial investigates Breast Cancer and is currently ongoing. Fudan University leads this study, which shows 11 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Jan 2026 — Present [monthly]
Unknown PHASE1/PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Jan 2026 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2022 — Apr 2023 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 6 earlier versions
-
Jun 2021 — Mar 2022 [monthly]
Recruiting PHASE1_PHASE2
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2019 — Jan 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2019 — Mar 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fudan University
- Jiangsu HengRui Medicine Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .